Review of the epidemiological literature on antidepressant use and breast cancer risk

References

• Seki K, Nagata I. Effects of a dopamine antagonist (metoclopramide) on the release of LH, FSH, TSH and PRL in normal women throughout the menstrual cycle. Acta Endocrinol. (Copenh.)122(2), 211–216 (1990).
   PubMedGoogle Scholar
• Seki K, Uesato T, Kato K. Effects of a dopamine antagonist (metoclopramide) on the release of the adenohypophyseal hormones in amenorrhoeic patients with and without hyperprolactinaemia. Acta Endocrinol. (Copenh.)101(2), 166–170 (1982).
   PubMedGoogle Scholar
• Molitch ME. Medication-induced hyperprolactinemia. Mayo Clin. Proc.80(8), 1050–1057 (2005).
   PubMed Web of Science ®Google Scholar
• Turkington RW. Prolactin secretion in patients treated with various drugs: phenothiazines, tricyclic antidepressants, reserpine, and methyldopa. Arch. Intern. Med.130(3), 349–354 (1972).
   PubMed Web of Science ®Google Scholar
• Emiliano AB, Fudge JL. From galactorrhea to osteopenia: rethinking serotonin-prolactin interactions. Neuropsychopharmacology29(5), 833–846 (2004).
   PubMed Web of Science ®Google Scholar
• Cowen PJ, Sargent PA. Changes in plasma prolactin during SSRI treatment: evidence for a delayed increase in 5-HT neurotransmission. J. Psychopharmacol.11(4), 345–348 (1997).
   PubMed Web of Science ®Google Scholar
• Welsch CW, Nagasawa H. Prolactin and murine mammary tumorigenesis: a review. Cancer Res.37(4), 951–963 (1977).
   PubMed Web of Science ®Google Scholar
• Hankinson SE, Willett WC, Michaud DS et al. Plasma prolactin levels and subsequent risk of breast cancer in postmenopausal women. J. Natl Cancer Inst.91(7), 629–634 (1999).
   PubMed Web of Science ®Google Scholar
• Brandes LJ, Arron RJ, Bogdanovic RP et al. Stimulation of malignant growth in rodents by antidepressant drugs at clinically relevant doses. Cancer Res.52(13), 3796–3800 (1992).
   PubMed Web of Science ®Google Scholar
• Stafford RS, MacDonald EA, Finkelstein SN. National patterns of medication treatment for depression, 1987 to 2001. Prim. Care Companion J. Clin. Psychiatry3(6), 232–235 (2001).
   PubMedGoogle Scholar
• Pirraglia PA, Stafford RS, Singer DE. Trends in prescribing of selective serotonin reuptake inhibitors and other newer antidepressant agents in adult primary care. Prim. Care Companion J. Clin. Psychiatry5(4), 153–157 (2003).
   PubMedGoogle Scholar
• Stagnitti MN. Trends in antidepressant use by the US civilian noninstitutionalized population, 1997 and 2002. Statistical Brief 76 from the Medical Expenditure Panel Survey. Agency for Healthcare Research and Quality, MD, USA (2005).
   Google Scholar
• Volpe DA, Ellison CD, Parchment RE, Grieshaber CK, Faustino PJ. Effects of amitriptyline and fluoxetine upon the in vitro proliferation of tumor cell lines. J. Exp. Ther. Oncol.3(4), 169–184 (2003).
   PubMedGoogle Scholar
• Danielson DA, Jick H, Hunter JR, Stergachis A, Madsen S. Nonestrogenic drugs and breast cancer. Am. J. Epidemiol.116(2), 329–332 (1982).
   PubMed Web of Science ®Google Scholar
• Wallace RB, Sherman BM, Bean JA. A case–control study of breast cancer and psychotropic drug use. Oncology39279–39283 (1982).
   Google Scholar
• Friedman GD. RE: Depression, antidepressant medication, and cancer: an editor comments. Am. J. Epidemiol.136(11), 1415–1416 (1992).
   Web of Science ®Google Scholar
• Selby JV, Friedman GD, Fireman BH. Screening prescription drugs for possible carcinogenicity: eleven to fifteen years of follow-up. Cancer Res.49(20), 5736–5747 (1989).
   PubMed Web of Science ®Google Scholar
• Kelly JP, Rosenberg L, Palmer JR et al. Risk of breast cancer according to use of antidepressants, phenothiazines, and antihistamines. Am. J. Epidemiol.150(8), 861–868 (1999).
   PubMed Web of Science ®Google Scholar
• Weiss SR, McFarland BH, Burkhart GA, Ho PT. Cancer recurrences and secondary primary cancers after use of antihistamines or antidepressants. Clin. Pharmacol. Ther.63(5), 594–599 (1998).
   PubMed Web of Science ®Google Scholar
• Ashbury FD, Madlensky L, Raich P et al. Antidepressant prescribing in community cancer care. Support. Care Cancer11(5), 278–285 (2003).
   PubMed Web of Science ®Google Scholar
• Cullivan R, Crown J, Walsh N. The use of psychotropic medication in patients referred to a psycho-oncology service. Psychooncology7(4), 301–306 (1998).
   PubMed Web of Science ®Google Scholar
• Fisch M, Callahan CM, Kesterson JG, Nichols C, Tierney WM. The use of an electronic patient record system to identify advanced cancer patients and antidepressant drug use. J. Palliat. Med.2(4), 403–409 (1999).
   PubMedGoogle Scholar
• Jaeger H, Morrow GR, Carpenter PJ, Brescia F. A survey of psychotropic drug utilization by patients with advanced neoplastic disease. Gen. Hosp. Psychiatry7(4), 353–360 (1985).
   PubMed Web of Science ®Google Scholar
• Cotterchio M, Kreiger N, Darlington G, Steingart A. Antidepressant medication use and breast cancer risk. Am. J. Epidemiol.151(10), 951–957 (2000).
   PubMed Web of Science ®Google Scholar
• Dalton SO, Johansen C, Mellemkjaer L et al. Antidepressant medications and risk for cancer. Epidemiology11(2), 171–176 (2000).
   PubMed Web of Science ®Google Scholar
• Kato I, Zeleniuch-Jacquotte A, Toniolo PG, Akhmedkhanov A, Koenig K, Shore RE. Psychotropic medication use and risk of hormone-related cancers: the New York University Women’s Health Study. J. Public Health Med.22(2), 155–160 (2000).
   PubMedGoogle Scholar
• Wang PS, Walker AM, Tsuang MT, Orav EJ, Levin R, Avorn J. Antidepressant use and the risk of breast cancer: a non-association. J. Clin. Epidemiol.54(7), 728–734 (2001).
   PubMed Web of Science ®Google Scholar
• Sharpe CR, Collet JP, Belzile E, Hanley JA, Boivin JF. The effects of tricyclic antidepressants on breast cancer risk. Br. J. Cancer86(1), 92–97 (2002).
   PubMed Web of Science ®Google Scholar
• van Schaik N, Graf U. Genotoxicity evaluation of five tricyclic antidepressants in the wing somatic mutation and recombination test in Drosophila melanogaster.Mutat. Res.260(1), 99–104 (1991).
   PubMed Web of Science ®Google Scholar
• van Schaik N, Graf U. Structure-activity relationships of tricyclic antidepressants and related compounds in the wing somatic mutation and recombination test of Drosophila melanogaster.Mutat. Res.286(2), 155–163 (1993).
   PubMed Web of Science ®Google Scholar
• Tamim H, Boivin JF, Hanley J, Stang M, Collet JP. Risk of breast cancer in association with exposure to two different groups of tricyclic antidepressants. Pharmacoepidemiol. Drug Saf. (2006) (E-pub ahead of print).
   PubMedGoogle Scholar
• Moorman PG, Grubber JM, Millikan RC, Newman B. Antidepressant medications and their association with invasive breast cancer and carcinoma in situ of the breast. Epidemiology14(3), 307–314 (2003).
   PubMed Web of Science ®Google Scholar
• Steingart A, Cotterchio M, Kreiger N, Sloan M. Antidepressant medication use and breast cancer risk: a case–control study. Int. J. Epidemiol.32(6), 961–966 (2003).
   PubMed Web of Science ®Google Scholar
• Chien C, Li CI, Heckbert SR, Malone KE, Boudreau DM, Daling JR. Antidepressant use and breast cancer risk. Breast Cancer Res. Treat.1–10 (2005).
   Google Scholar
• Coogan PF, Palmer JR, Strom BL, Rosenberg L. Use of selective serotonin reuptake inhibitors and the risk of breast cancer. Am. J. Epidemiol.162(9), 835–838 (2005).
   PubMed Web of Science ®Google Scholar
• Gonzalez-Perez A, Garcia Rodriguez LA. Breast cancer risk among users of antidepressant medications. Epidemiology16(1), 101–105 (2005).
   PubMed Web of Science ®Google Scholar
• Haque R, Enger SM, Chen W, Petitti DB. Breast cancer risk in a large cohort of female antidepressant medication users. Cancer Lett.221(1), 61–65 (2005).
   PubMed Web of Science ®Google Scholar
• Ormandy CJ, Hall RE, Manning DL et al. Coexpression and cross-regulation of the prolactin receptor and sex steroid hormone receptors in breast cancer. J. Clin. Endocrinol. Metab.82(11), 3692–3699 (1997).
   PubMed Web of Science ®Google Scholar
• Gutzman JH, Miller KK, Schuler LA. Endogenous human prolactin and not exogenous human prolactin induces estrogen receptor alpha and prolactin receptor expression and increases estrogen responsiveness in breast cancer cells. J. Steroid Biochem. Mol. Biol.88(1), 69–77 (2004).
   PubMed Web of Science ®Google Scholar
• Fulton-Kehoe D, Rossing MA, Rutter C, Mandelson MT, Weiss NS. Use of antidepressant medications in relation to the incidence of breast cancer. Br. J. Cancer94(7), 1071–1078 (2006).
   PubMed Web of Science ®Google Scholar
• Bahl S, Cotterchio M, Kreiger N. Use of antidepressant medications and the possible association with breast cancer risk. A review. Psychother. Psychosom.72(4), 185–194 (2003).
   PubMed Web of Science ®Google Scholar
• Lawlor DA, Juni P, Ebrahim S, Egger M. Systematic review of the epidemiologic and trial evidence of an association between antidepressant medication and breast cancer. J. Clin. Epidemiol.56(2), 155–163 (2003).
   PubMed Web of Science ®Google Scholar
• Jurek AM, Greenland S, Maldonado G, Church TR. Proper interpretation of non-differential misclassification effects: expectations vs observations. Int. J. Epidemiol.34(3), 680–687 (2005).
   PubMed Web of Science ®Google Scholar
• Cotterchio M, Kreiger N, Darlington G, Steingart A. Comparison of self-reported and physician-reported antidepressant medication use. Ann. Epidemiol.9(5), 283–289 (1999).
   PubMed Web of Science ®Google Scholar
• Boudreau DM, Daling JR, Malone KE, Gardner JS, Blough DK, Heckbert SR. A validation study of patient interview data and pharmacy records for antihypertensive, statin, and antidepressant medication use among older women. Am. J. Epidemiol.159(3), 308–317 (2004).
   PubMed Web of Science ®Google Scholar
• Ader R, Cohen N, Felten D. Psychoneuroimmunology: interactions between the nervous system and the immune system. Lancet345(8942), 99–103 (1995).
   PubMed Web of Science ®Google Scholar
• Penninx BW, Guralnik JM, Pahor M et al. Chronically depressed mood and cancer risk in older persons. J. Natl Cancer Inst.90(24), 1888–1893 (1998).
   PubMedGoogle Scholar
• Persky VW, Kempthorne-Rawson J, Shekelle RB. Personality and risk of cancer: 20-year follow-up of the Western Electric Study. Psychosom. Med.49(5), 435–449 (1987).
   PubMed Web of Science ®Google Scholar
• Dalton SO, Mellemkjaer L, Olsen JH, Mortensen PB, Johansen C. Depression and cancer risk: a register-based study of patients hospitalized with affective disorders, Denmark, 1969–1993. Am. J. Epidemiol.155(12), 1088–1095 (2002).
   PubMed Web of Science ®Google Scholar
• Hjerl K, Andersen EW, Keiding N et al. Breast cancer risk among women with psychiatric admission with affective or neurotic disorders: a nationwide cohort study in Denmark. Br. J. Cancer81(5), 907–911 (1999).
   PubMed Web of Science ®Google Scholar
• Lillberg K, Verkasalo PK, Kapr J, Teppo L, Helenius H, Koskenvuo M. A prospective study of life satisfaction, neuroticism and breast cancer risk (Finland). Cancer Causes Control13(2), 191–198 (2002).
   PubMed Web of Science ®Google Scholar